Current Projects: Innovation and Technology Policy

  • Innovation, Health and Wealth: A Formative and Summative Evaluation

    The Department of Health’s strategy for improving care and creating greater wealth through innovation, known as ‘Innovation, Health and Wealth’ (IHW), has the potential to systematically change the way the NHS operates. RAND Europe is evaluating whether and how IHW actions are working as planned, and contributing to achieving the strategy's overarching aims.

  • Evaluating the Assessment Process for the Impact Element of REF 2014

    Following RAND Europe's evaluation of the Research Excellence Framework submission process, the four UK higher education funding bodies have commissioned an evaluation of the assessment process for the impact element of the REF 2014.

  • Validating the Outcomes of the 'Science 2.0: Science in Transition' Public Consultation

    ‘Science 2.0’ describes the on-going evolution in the modus operandi of doing research and organising science in Europe. RAND Europe is reviewing the public consultation on this EU project and has developed an interactive website on which participants and interested individuals can comment on the validation process of the public consultation.

  • Evaluating the Impact of the NIHR Invention for Innovation (i4i) Programme

    The i4i programme supports the development of innovative medical technologies and their translation into clinical practice. RAND Europe is evaluating i4i to identify its impacts and the factors influencing performance.

  • Understanding the Relative Valuations of Research Impact

    To contribute to the Medical Research Council's objective of funding studies that "deliver user/beneficiary views on the contribution of academic research and MRC input," researchers are refining and adapting a survey-based approach known as Best-Worst Scaling (BWS) to analyse the relative valuations of research impact as perceived by the general population and researchers.

  • Exploring the Links Between Big Data and Public Policy

    Understanding the context and impacts of the complex problems associated with big data, as well as related cultural and governance issues and policy frameworks, is important to businesses, governments, research organisations, citizens and policymakers. RAND Europe connects diverse strands across these areas.

  • Evaluating Social Innovation Pilot Projects

    A series of social innovation pilot projects across Europe aim to support the growth of European social finance markets and the development of capacities within social business and young entrepreneurship. RAND Europe and Ecorys are evaluating these pilots and hosting a series of interactive workshops to encourage an exchange of experiences.

  • Estimating the Value of Mobile Telephony in Mobile Network 'Not-Spots'

    Around 80,000 premises in the UK are located in areas without mobile phone coverage – referred to as “not-spots”. Researchers are estimating the social, economic and environmental impacts associated with eliminating mobile not-spot areas in England.

  • Scoping the Impact of EU Membership on UK Health Research

    To help frame the debate on future EU membership in the context of UK health research, RAND Europe is assessing the benefits and burdens of membership. This research, for the Department of Health, will not only focus on funding, but also look at other aspects such as research environment, network effects, and knowledge spillovers. The project will include a series of scenario-based workshops to explore future impact of EU funding.

  • Evaluating the Submission Process for the Research Excellence Framework's Impact Element

    To formulate evidence-based conclusions and recommendations for improving the processes of preparing submissions for impact assessment, the higher education funding councils for England, Scotland and Wales asked RAND Europe to work with a sample of higher education institutions to evaluate the submission process for the impact element of the Research Excellence Framework (REF) 2014.

  • Understanding Physicians' Decision-Making Process Concerning Hepatitis-C Treatment

    When treating patients for Hepatitis-C, physicians may be influenced by many factors: their prior experience, the health and social care systems more broadly, or clinical, social and behavioural, or demographic factors. To better understand this decision-making process, GlaxoSmithKline commissioned RAND Europe to investigate the comparative influence and importance of specific factors and combinations of factors and their trade-offs.

  • Could the Strengthening of Health Systems in Africa Improve Industrial Development?

    The performance of health systems is a key determinant of the inclusiveness of economic growth. Exclusionary, poor quality health care worsens impoverishment, while inclusive health care redistributes the benefits of growth toward the poor and ill. With Kenya and Tanzania as case studies, RAND Europe is exploring the extent to which unexploited potential synergies between industrial development and health systems can strengthen and contribute to faster and more inclusive growth.

  • Evaluating the Success of Research Collaborations in Improving Applied Health Research

    The National Institute for Health Research established nine Collaborations for Leadership in Applied Health Research and Care (CLAHRCs) and has commissioned RAND Europe and the Health Economics Research Group at Brunel University to evaluate and learn from the CLAHRCs approach. The goal of the project is to focus on the gap in translating applied research advances into innovations in health and social care, for patient benefit.

  • What Impact Will Online Energy-Efficiency Ratings Have on the EU’s Lisbon Strategy?

    The EU's Lisbon Strategy has a targeted goal of 20% energy efficiency gains by 2020. EU Directive 2010/30/EC has therefore mandated energy efficiency labels on a wider variety of products than was previously the case and further requires this information to be made available online. RAND Europe is assessing the impacts of measures intended to implement this requirement by ensuring that A-G Energy Efficiency rating information is displayed in online sales, rental, and search environments.

  • Assessing the Evidence Base for Pharmaceutical R&D Models

    As research-based drug development is widely viewed as crucial to improving patient health, the pharmaceuticals sector is heavily reliant — and spends a great deal — on research and development. However, there is considerable debate about different R&D models: for example, is it more successful when conducted in a closed, in-house environment or through open networks and partnerships? To help answer this question, Pfizer has asked RAND Europe to investigate the evidence base.